Elecoglipron口服小分子GLP-1受体激动剂治疗肥胖或超重的2期随机对照试验
VISTA研究是一项多中心、双盲、随机、安慰剂对照的2期剂量探索试验,纳入310例无糖尿病的肥胖或超重成人,评估每日一次口服Elecoglipron的疗效与安全性。安全性特征与GLP-1受体激动剂类一致。
要点
- 最常见不良事件为恶心、便秘、腹泻、头痛和呕吐,与GLP-1类预期一致。
核心结论
- 每日口服Elecoglipron在肥胖或超重成人中产生有临床意义的体重下降,安全性和耐受性与GLP-1受体激动剂类一致,支持开展3期研究。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照的2期剂量探索研究,总治疗时长36周,在澳大利亚、加拿大、德国、日本、台湾、英国和美国招募成人参与者。
- 纳入标准为年龄≥18岁、BMI≥30 kg/m2的肥胖或BMI≥27 kg/m2的超重且至少有一种体重相关合并症、无2型糖尿病。
- 310名参与者按2:3:3:3:3:5比例随机分配至Elecoglipron 5 mg、15 mg、50 mg、75 mg(每周滴定)或75 mg(每2周滴定)或匹配安慰剂组。
- 双主要终点为第26周体重较基线的百分比变化和体重减轻≥5%的参与者比例;安全性在所有接受至少一剂研究治疗的参与者中评估。
主要发现
- Elecoglipron各剂量组不良事件报告率为84%(27/32)至98%(48/49),安慰剂组为84%(68/81);最常见不良事件为恶心、便秘、腹泻、头痛和呕吐。
关键数值与推荐
- 肥胖定义为BMI≥30 kg/m2;超重定义为BMI≥27 kg/m2且至少有一种体重相关合并症。
- 双主要终点:第26周体重较基线百分比变化和体重减轻≥5%的参与者比例。
- 随机分配比例2:3:3:3:3:5至Elecoglipron 5 mg、15 mg、50 mg、75 mg(每周滴定)、75 mg(每2周滴定)或安慰剂。
临床怎么用
- 每日一次口服Elecoglipron无需饮食或液体限制,可能提高用药便利性。
- 2期数据支持在肥胖或超重人群中进一步开展3期研究以确认疗效和长期安全性。
局限性
- 本研究为2期剂量探索研究,样本量310例,治疗时长36周,主要终点为第26周。
- 研究排除了2型糖尿病患者,结论不直接适用于该人群。
- 开放标签扩展或长期心血管结局尚未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elecoglipron (AZD5004) is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered once daily without food or fluid restriction, in development for weight management in people living with obesity or overweight and type 2 diabetes. We assessed the efficacy, safety, and tolerability of elecoglipron versus placebo in participants with obesity or overweight and at least one weight-related condition without diabetes. METHODS: In this double-blind, randomised, controlled, phase 2 dose-ranging study with a total treatment duration of 36 weeks, adult participants were recruited from medical research centres and hospitals in Australia, Canada, Germany, Japan, Taiwan, the UK, and the USA. Participants were aged 18 years or older living with obesity (BMI ≥30 kg/m2) or with overweight (BMI ≥27 kg/m2) with at least one weight-related condition and without type 2 diabetes. Eligible participants were randomly assigned in a 2:3:3:3:3:5 ratio to receive 5 mg, 15 mg, 50 mg, 75 mg (weekly titration), or 75 mg (every 2-week titration) of elecoglipron or matching placebo. Elecoglipron was administered as oral once-daily tablets without titration (5 mg and 15 mg) and as three different dose-titration regimens. The daily dose of 50 mg was evaluated using an every-4-weeks dose-escalation schedule, while 75 mg was assessed with weekly or every 2-week dose-escalation schedules. Participants, treating physicians, and sponsor were masked to the treatment allocation. The dual primary endpoints were percent change in bodyweight from baseline and the proportion of patients reaching at least 5% weight loss at week 26. Safety and tolerability were assessed in all participants who received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov (NCT06579092) and is completed. FINDINGS: From Oct 8, 2024, to Feb 18, 2025, 472 individuals were screened for potential study inclusion, 162 did not meet the inclusion criteria, and 310 participants were randomly assigned to the varied elecoglipron groups or placebo. 288 participants (93%) completed the study and 231 (75%) completed the assigned treatment. The mean age of participants was 48·4 years (SD 13·7), 225 (73%) were female, 85 (27%) were male, their mean bodyweight was 106·9 kg (SD 24·1), and their mean BMI was 38·2 kg/m2 (SD 7·2). At week 26, the estimated mean change from baseline in bodyweight was between -2·6% (5 mg elecoglipron), and -10·5% (75 mg with weekly titration steps) compared with -0·6% with placebo. The estimated proportion of participants reaching weight reductions of at least 5% at week 26 was 40·4-88·8% with elecoglipron versus 15·6% with placebo. Adverse events were reported by 84% (27 of 32) to 98% (48 of 49) of participants across elecoglipron doses compared with 84% (68 of 81) in the placebo group, the most common being nausea, constipation, diarrhoea, headache, and vomiting. INTERPRETATION: Daily oral elecoglipron demonstrated clinically meaningful weight reductions and a safety and tolerability profile consistent with the GLP-1 receptor agonist class in this phase 2 dose-ranging study, supporting phase 3 investigation in people living with obesity or overweight. FUNDING: AstraZeneca.
引用
- Davies MJ, Aroda VR, Rosenstock J, et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet. 2026. PMID: 42259337. doi:10.1016/S0140-6736(26)00748-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。